Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Climb 4.7% - What's Next?

Key Points

• Recursion Pharmaceuticals shares rose 4.7% to $3.875 during midday trading, reaching as high as $4.00, although trading volume was 45% below its average.
• Analyst sentiment remains mixed, with an overall “Hold” rating and a consensus price target of $8.06; ratings include two Buys, two Holds, and one Sell.
• The company recently missed quarterly expectations, reporting a $0.25 per-share loss versus the $0.24 expected and revenue of $7.67 million versus estimates of $10.97 million.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s stock price traded up 4.7% during mid-day trading on Tuesday. The company traded as high as $4.00 and last traded at $3.8750. 10,114,293 shares were traded during trading, a decline of 45% from the average daily volume of 18,239,877 shares. The stock had previously closed at $3.70.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on RXRX. Morgan Stanley set a $5.30 price target on shares of Recursion Pharmaceuticals in a research note on Monday, August 17th. Weiss Ratings reissued a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th. Finally, Wall Street Zen upgraded Recursion Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 29th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $8.06.

Recursion Pharmaceuticals Price Performance

The stock's 50-day moving average price is $3.34 and its 200 day moving average price is $3.33. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of -3.71 and a beta of 1.07. The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.The firm had revenue of $7.67 million for the quarter, compared to analyst estimates of $10.97 million. During the same period last year, the business earned ($0.41) earnings per share. Equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -0.94 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Blake Borgeson sold 40,000 shares of the firm's stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total transaction of $158,400.00. Following the completion of the transaction, the director directly owned 6,218,287 shares of the company's stock, valued at approximately $24,624,416.52. This trade represents a 0.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 22,408 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $3.52, for a total transaction of $78,876.16. Following the sale, the chief executive officer owned 2,072,890 shares in the company, valued at approximately $7,296,572.80. This trade represents a 1.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 122,408 shares of company stock valued at $434,976. Corporate insiders own 6.65% of the company's stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. MCF Advisors LLC bought a new stake in Recursion Pharmaceuticals during the second quarter worth about $27,000. Integral Investment Advisors Inc. acquired a new position in shares of Recursion Pharmaceuticals in the 1st quarter worth approximately $39,000. MQS Management LLC bought a new stake in Recursion Pharmaceuticals during the 1st quarter worth approximately $41,000. Fund Advisors of America Inc FL bought a new stake in Recursion Pharmaceuticals during the 2nd quarter worth approximately $45,000. Finally, QRG Capital Management Inc. acquired a new stake in shares of Recursion Pharmaceuticals in the first quarter valued at $47,000. 89.06% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc NASDAQ: RXRX is a biotechnology company that uses artificial intelligence, automation, and large-scale biological experimentation to accelerate the discovery and development of medicines. Its technology platform, known as the Recursion Operating System, integrates data from biology, chemistry, imaging, and machine learning to identify potential drug candidates and better understand disease biology.

The company develops therapies for areas including oncology, rare diseases, and neurological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.